AbbVie updates 2025 earnings guidance to reflect $2.7 billion IPR&D expense
NegativeFinancial Markets

AbbVie has revised its earnings guidance for 2025, now reflecting a significant $2.7 billion expense related to in-process research and development (IPR&D). This update is crucial as it indicates the company's ongoing investment in innovation, but also raises concerns about its financial health and future profitability. Stakeholders will be closely watching how this impacts AbbVie's market position and overall strategy moving forward.
— Curated by the World Pulse Now AI Editorial System